Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bright Minds Biosciences Inc. (DRUG.CN)
New York, NY, CA
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.85% | +5.63% | -9.15% | -5.21% | +38.68% | +1.30% | +151.56% | +2,471.72% | +285.76% | +161.68% | +161.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-173.9% Q1'26: -164.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +5,784.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+59.6% Q1'26: +36.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
| Metric |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 5 EPS Ana. |
Sep 2027 7 Rev. Ana. 6 EPS Ana. |
Sep 2028 6 Rev. Ana. 6 EPS Ana. |
Sep 2029 4 Rev. Ana. 3 EPS Ana. |
Sep 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
38.93M
38.93M – 38.93M
|
50.00M
50.00M – 50.00M
+28.4% YoY
|
141.67M
141.67M – 141.67M
+183.3% YoY
|
271.27M
271.27M – 271.27M
+91.5% YoY
|
| EBITDA |
-2.72M
|
-13.86M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-2.79M
|
-13.94M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-2.80M
est: -4.74M (+40.9%)
|
-12.23M
est: -14.03M (+12.9%)
|
-43.87M
-55.98M – -31.76M
-212.6% YoY
|
-73.58M
-141.84M – -5.31M
-67.7% YoY
|
-96.10M
-132.96M – -59.23M
-30.6% YoY
|
-95.90M
-95.90M – -95.90M
+0.2% YoY
|
-59.22M
-59.22M – -59.22M
+38.2% YoY
|
| SGA |
1.44M
|
2.57M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.65
est: -1.10 (+40.9%)
|
-1.78
est: -2.04 (+12.8%)
|
-6.57
-8.14 – -4.62
-222.2% YoY
|
-11.90
-20.62 – -0.77
-81.1% YoY
|
-14.75
-19.33 – -8.61
-23.9% YoY
|
-13.94
-13.94 – -13.94
+5.5% YoY
|
-8.61
-8.61 – -8.61
+38.2% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-20 | Piper Sandler | Overweight | Overweight | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.13% | 1.94M | 0.60% |
| 2 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.06% | 576.0K | 0.20% |
| 3 | iShares Russell 2000 Growth ETF IWO | 0.04% | 5.43M | 0.24% |
| 4 | Fidelity Enhanced Small Cap ETF FESM | 0.03% | 1.45M | 0.28% |
| 5 | iShares Russell 2000 BuyWrite ETF IWMW | 0.02% | 10.6K | 0.39% |
| 6 | iShares Russell 2000 ETF IWM | 0.02% | 15.43M | 0.19% |
| 7 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.02% | 58.5K | 0.25% |
| 8 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.02% | 1.01M | 0.30% |
| 9 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.02% | 465.0K | 0.30% |
| 10 | iShares Russell 2500 ETF SMMD | 0.01% | 273.4K | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jan Torleif Pedersen | Chief Science Officer & Director | 730.3K | — |
| Stephen D. Collins | Chief Medical Officer | 327.5K | — |
| Ryan E. S. K. Cheung | CFO & Corporate Secretary | 134.2K | male |
| Alex Vasilkevich | Chief Operating Officer & Senior Scientific Officer | — | male |
| Emer Leahy | Consultant | — | — |
| Ian McDonald | Co-Founder, Chief Executive Officer, President & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DRUG.CN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
